• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

    10/25/24 9:42:03 PM ET
    $TIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TIL alert in real time by email
    SC 13G/A 1 ff4031865_13ga1-instil.htm


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     


    Schedule 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     
     



    Instil Bio, Inc.
    (Name of Issuer)

    Common Stock, par value $0.000001
    (Title of Class of Securities)

    45783C200
    (CUSIP Number)

    October 10, 2024
    (Date of Event which Requires Filing of this Statement)
     
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)
    ____________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
        The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP No.:45783C200
    13G
     Page 2 of 12 Pages


    1
    NAMES OF REPORTING PERSONS
     
     
    Boxer Capital, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No.:45783C200
    13G
     Page 3 of 12 Pages


    1
    NAMES OF REPORTING PERSONS
     
     
    Boxer Asset Management Inc.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Bahamas
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     
     

     
    CUSIP No.:45783C200
    13G
     Page 5 of 12 Pages


    1
    NAMES OF REPORTING PERSONS
     
     
    Joe Lewis
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United Kingdom
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    CUSIP No.:45783C200
    13G
     Page 6 of 12 Pages


    1
    NAMES OF REPORTING PERSONS
     
     
    MVA Investors, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No.:45783C200
    13G
     Page 7 of 12 Pages


    1
    NAMES OF REPORTING PERSONS
     
     
    Aaron I. Davis
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    355,500
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    355,500
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    355,500
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    5.5%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     
     

    CUSIP No.:45783C200
    13G
     Page 8 of 12 Pages


    1
    NAMES OF REPORTING PERSONS
     
     
    Boxer Capital Management, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    355,500
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    355,500
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    355,500
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    5.5%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO; IA
     
     
     
     
     

    This Amendment No. 1 (“Amendment No. 1”) amends and supplements the statement on Schedule 13G initially filed on September 27, 2024 (the “Original Filing”) by Boxer Capital, LLC (“Boxer Capital”), Boxer Asset Management Inc. (“Boxer Management”), Joe Lewis, Aaron I. Davis and MVA Investors, LLC (“MVA Investors”) regarding the Common Stock of Instil Bio, Inc. On October 10, 2024, Boxer Capital entered into an investment management agreement (the “IMA”) with Boxer Capital Management LLC (“BCM”), a registered investment advisor controlled by Mr. Davis. Pursuant to the IMA, Boxer Capital has delegated exclusive voting and investment power over its investment portfolio to BCM. Consequently, BCM has acquired beneficial ownership of the securities held in Boxer Capital’s investment portfolio and, without reflecting any change in its economic interest in such securities, Boxer Capital has thereby ceased to beneficially own the securities held in its investment portfolio, including shares of Common Stock. To the extent applicable, the Original Filing, as hereby amended, is hereby adopted by BCM as its original filing on Schedule 13G regarding the Common Stock. The Original Filing, as amended, remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment No. 1. Capitalized terms used and not defined in this Amendment No. 1 have the meanings set forth in the Original Filing, as amended. Boxer Capital, Boxer Management, Mr. Lewis and MVA Investors report herein that they have ceased to beneficially own more than 5% of the outstanding shares of Common Stock. To the extent available, BCM and Mr. Davis may in the future report their beneficial ownership of shares of Common Stock on Schedule 13G pursuant to Rule 13d-1(b).
    Item 2(a): Name of Person Filing
    Item 2(a) is hereby amended and restated to read as follows:

    This Schedule 13G is jointly filed by Boxer Capital, Boxer Management, Mr. Lewis, MVA Investors, Mr. Davis and BCM (collectively, the “Reporting Persons”).

    Boxer Management is the managing member and majority owner of Boxer Capital. Mr. Lewis is the sole indirect owner of and controls Boxer Management. MVA Investors is the independent, personal investment vehicle of certain employees of BCM. BCM is a registered investment advisor, providing investment management services to Boxer Capital. Mr. Davis is the Managing Member of BCM and is a member of and has voting and dispositive power over securities beneficially held by MVA Investors and BCM. With his immediate family, Mr. Davis indirectly owns the membership interests in BCM.

    Item 2(b): Address of Principal Business Office or, if None, Residence

    Item 2(b) is hereby amended and restated to read as follows:

    The principal business address of Boxer Capital, MVA Investors, Mr. Davis and BCM is: 12860 El Camino Real, Suite 300, San Diego, CA 92130. The principal business address of Boxer Management and Mr. Lewis is: Albany Financial Center, Suite 207, Lewis Drive, N7776, New Providence, Bahamas.

    Item 2(c): Citizenship

    Item 2(c) is hereby amended and restated to read as follows:

    Boxer Capital, MVA Investors and BCM are limited liability companies organized under the laws of Delaware. Boxer Management is a Bahamian international business company. Mr. Lewis is a citizen of the United Kingdom. Mr. Davis is a citizen of the United States of America.

    Item 4: Ownership

    Item 4 is hereby amended and restated to read as follows:



    (a)
    Amount beneficially owned: BCM and Mr. Davis beneficially own 355,500 shares of Common Stock. The Reporting Persons beneficially own, in the aggregate, 355,500 shares of Common Stock.
    (b)
    Percent of class: All percentages of beneficial ownership set forth herein are based on 6,503,913 shares of Common Stock reported outstanding on August 9, 2024 in the Form 10-Q filed by the Issuer with the Securities and Exchange Commission on August 13, 2024. The number of shares of Common Stock beneficially owned by the Reporting Persons in the aggregate represents 5.5% of the Issuer’s outstanding shares of Common Stock.
    (c)
    Number of shares as to which such person has:
    (i)
    sole power to vote or to direct the vote: None of the Reporting Persons has sole power to vote or to direct the vote of any shares of Common Stock.
    (ii)
    shared power to vote or to direct the vote: BCM and Mr. Davis have shared power to vote or to direct the vote of 355,500 shares of Common Stock.
    (iii)
    sole power to dispose or to direct the disposition of: None of the Reporting Persons has sole power to dispose or to direct the disposition of any shares of Common Stock.
    (iv)
    shared power to dispose or to direct the disposition of: BCM and Mr. Davis have shared power to dispose or to direct the disposition of 355,500 shares of Common Stock.
    Item 5: Ownership of Five Percent or Less of a Class
    With respect to Boxer Capital, Boxer Management, Mr. Lewis and MVA Investors:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.
    Item 6: Ownership of More than Five Percent on Behalf of Another Person

    Item 6 is hereby amended and restated to read as follows:

    Other than as may result from indirect interests of investors in Boxer Capital and MVA Investors, no persons other than the Reporting Persons have the right to receive or the power to direct the receipt of dividends, or proceeds of sale of the securities disclosed herein.

    Item 10: Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Exhibits
     
     
    2
     
    Joint Filing Agreement, dated October 25, 2024, among the Reporting Persons.






    SIGNATURES
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Dated:  October 25, 2024


     
     BOXER CAPITAL, LLC
     
     
     
     
     
     
     
     By:
    /s/ Aaron I. Davis
     
     
     
    Name:
    Aaron I. Davis
     
     
     
    Title:
    Authorized Signatory
     
     
     
     
     
     
     
    BOXER ASSET MANAGEMENT INC.
     
     
     
     
     
     
     
    By:
    /s/ Paul Higgs
     
     
     
    Name:
    Paul Higgs
     
        Title:
    Director
     
             
      JOSEPH C. LEWIS
     
             
      /s/ Joseph C. Lewis
     
      Joseph C. Lewis, Individually
     
             
      MVA INVESTORS, LLC
     
             
      By:
    /s/ Aaron I.  Davis
     
        Name:
    Aaron I. Davis
     
        Title:
    Authorized Signatory
     
             
      AARON I. DAVIS
     
             
      /s/ Aaron I. Davis
     
      Aaron I. Davis, Individually
     
             
             
      BOXER CAPITAL MANAGEMENT, LLC
     
             
      By:
    /s/ Aaron I. Davis
     
        Name:
    Aaron I. Davis
     
        Title:
    Managing Member
     
             

     
       

       



     
    Get the next $TIL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TIL

    DatePrice TargetRatingAnalyst
    1/7/2025$11.00 → $52.00Hold → Buy
    Jefferies
    1/7/2025$11.00 → $52.00Hold → Buy
    Truist
    11/4/2024Mkt Perform
    JMP Securities
    4/12/2024$5.00 → $11.00Buy → Hold
    Jefferies
    11/1/2022$16.00 → $6.00Buy → Hold
    Truist
    11/1/2022Outperform → Market Perform
    Cowen
    8/13/2021$34.00Outperform
    Robert W. Baird
    8/13/2021$34.00Outperform
    Baird
    More analyst ratings

    $TIL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, anticipated in 1H 2025 Enrollment of 1L NSCLC patients in trial of AXN-2510/IMM2510 and chemotherapy by ImmuneOnco in China anticipated to begin in Q2 2025 with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC anticipated before the end of 2025, assuming receipt of necessary regulatory approvals DALLAS, March 04, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("I

      3/4/25 7:09:26 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

      ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China ImmuneOnco announced initial clinical data from the 1L advanced NSCLC trial in China is expected as early as 2H 2025 Instil is targeting initiation of a potential first-line advanced NSCLC clinical trial of IMM2510/SYN-2510 combined with chemotherapy in 2H 2025, assuming necessary regulatory approvals DALLAS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (NASDAQ:TIL, "Instil")), today announced clinical progress of IMM2510/SYN-2510 in China by its collaborator, ImmuneOnco Biopharmaceutica

      1/14/25 7:00:37 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      Licensed SYN-2510, a potential best-in-class PD-L1xVEGF bispecific antibody, for global ex-China development and commercialization Clinical data update for SYN-2510/IMM2510 in China from ImmuneOnco anticipated in 1H 2025 Initiation of Phase 1b/2 SYN-2510/IMM2510 + chemotherapy combination in first-line non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) anticipated in late 2024 and 1H 2025, respectively, by ImmuneOnco in China U.S. clinical study of SYN-2510/IMM2510 in NSCLC initiation targeted for 2H 2025 DALLAS, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing a

      11/13/24 7:00:00 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    SEC Filings

    See more
    • SEC Form DEFR14A filed by Instil Bio Inc.

      DEFR14A - Instil Bio, Inc. (0001789769) (Filer)

      5/2/25 5:00:20 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Instil Bio Inc.

      DEFA14A - Instil Bio, Inc. (0001789769) (Filer)

      4/14/25 4:30:40 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Instil Bio Inc.

      DEF 14A - Instil Bio, Inc. (0001789769) (Filer)

      4/14/25 4:30:08 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    Leadership Updates

    Live Leadership Updates

    See more
    • Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1'23 Reprioritization of resources with enrollment deferred in DELTA-2 trial of ITIL-168 First patient with non-small cell lung cancer dosed with ITIL-306, the first engineered TIL therapy using CoStAR Platform, with plans to share clinical data in 2023 Appointment of cell therapy pioneer Dr. Robert Hawkins as Head of Research and Development, and resignation of Chief Medical Officer, Dr. Zachary Roberts Company confirms cash runway into 2025 with anticipated sale-leaseback transaction of its Tarzana manufacturing facility DALLAS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("

      11/14/22 4:07:40 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer

      DALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (NASDAQ:TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced the appointment of Tim Moore to the role of Chief Operating Officer. Tim Moore has more than three decades of leadership experience in biopharmaceutical manufacturing and operations, including at Genentech, Kite and most recently PACT Pharma. From 2016 to 2019, Mr. Moore was Executive Vice President, Technical Operations at Kite Pharma, where he was responsible for technical operations and successfully launched Yescarta®, one of the fi

      9/6/22 7:00:00 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

      SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

      11/14/24 6:59:16 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

      SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

      11/14/24 5:48:56 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Instil Bio Inc.

      SC 13G/A - Instil Bio, Inc. (0001789769) (Subject)

      10/25/24 9:42:03 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CFO and CBO Laumas Sandeep

      4 - Instil Bio, Inc. (0001789769) (Issuer)

      4/28/25 5:00:42 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CEO and Chairman Crouch Bronson

      4 - Instil Bio, Inc. (0001789769) (Issuer)

      4/28/25 5:00:15 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CFO and CBO Laumas Sandeep

      4 - Instil Bio, Inc. (0001789769) (Issuer)

      9/23/24 1:12:01 PM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TIL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Instil Bio upgraded by Jefferies with a new price target

      Jefferies upgraded Instil Bio from Hold to Buy and set a new price target of $52.00 from $11.00 previously

      1/7/25 8:29:55 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Instil Bio upgraded by Truist with a new price target

      Truist upgraded Instil Bio from Hold to Buy and set a new price target of $52.00 from $11.00 previously

      1/7/25 8:29:34 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on Instil Bio

      JMP Securities initiated coverage of Instil Bio with a rating of Mkt Perform

      11/4/24 7:41:54 AM ET
      $TIL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care